Acrivon Therapeutics, Inc. Common Stock (ACRV) SC 13GAcrivon Therapeutics / Sands Capital Life Sciences Pulse Fund II ownership change

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The calculation of beneficial ownership of the Reporting Persons (as defined below) is based on 20,859,823 shares of common stock issued and outstanding as of November 16, 2022, as reported by the Issuer in its prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on November 16, 2022, giving effect to the shares issued in the Issuer’s initial public offering and concurrent private placement.

The calculation of beneficial ownership of the Reporting Persons (as defined below) is based on 20,859,823 shares of common stock issued and outstanding as of November 16, 2022, as reported by the Issuer in its prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on November 16, 2022, giving effect to the shares issued in the Issuer’s initial public offering and concurrent private placement.

Frank M. Sands holds ultimate voting and investment power over securities held by Sands Capital Life Sciences Pulse Fund II, L.P., and thus may be deemed to beneficially own a total of 1,652,606 shares of Common Stock.

Name of Person Filing: This Schedule 13G is being filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P. (“Sands Pulse Fund II”) and Frank M. Sands (together with Sands Pulse Fund II, the “Reporting Persons”).

Address of Principal Business Office or, if None, Residence: The principal business address of each of the Reporting Persons, Sands Pulse GP L.P. and Sands Pulse Fund II GP LLC is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.

Citizenship: Sands Pulse Fund II is organized under the laws of the Cayman Islands. Frank M. Sands is a citizen of the United States.

Title and Class of Securities: The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, par value $0.001 per share.

CUSIP No.: 004890109

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

☐ Broker or dealer registered under Section 15 of the Act;

☐ Bank as defined in Section 3(a)(6) of the Act;

☐ Insurance company as defined in Section 3(a)(19) of the Act;

☐ Investment company registered under Section 8 of the Investment Company Act of 1940;

☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:                     .

Ownership

Ownership of Five Percent or Less of a Class.

Ownership of more than Five Percent on Behalf of Another Person.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Identification and classification of members of the group.

Notice of Dissolution of Group.

Certifications.